I think the share price for At1 is being unfairly tarnished by the Australian market and perceptions of it. It's fine with me if it stays low for a while. Anything buys around IPO price should be justified as a decent investment shortly in 2022. " Dr Sambursky said that on a global scale, however, rapid testing for coronavirus looked set to be a significant part of the diagnostics industry for the long term.."
